|
|
Article: Celgene Corporation Reports Strong Operating Performance in Second Quarter as Total Sales Increase 100 Percent and Profits Rise; * Product Sales Driven by Increase of 93.4 Percent, year-over-year, in THALOMID(R) Revenues and Reintroduction of ALKERAN(R) * Quarterly Earnings of $0.03 per Diluted Share Exceeds Earnings Consensus * 2003 Full Year Financial Guidance Raised * R&D Investment Increased to Accelerate REVIMID(TM) Regulatory Approval.
- Article from:
- PR Newswire
- Article date:
- July 24, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Celgene Corporation today announced earnings per diluted share of $0.03 driven by strong THALOMID(R) (thalidomide) and ALKERAN(R) (melphalan) Tablets and ALKERAN(R) (melphalan HCl) for Injection sales. THALOMID sales were approximately $54.8 million up 93.4 percent for the second quarter of 2003 compared to $28.3 million in the second quarter of 2002. Total revenue was $67.3 million, an increase of 100.1 percent over the prior-year quarter. Celgene posted net income of $2.9 million, or $0.03 per diluted share compared to a net loss of $1.7 million or ($0.02) per diluted share year-over-year.
THALOMID sales rose 20.2 percent quarter-over-quarter to $54.8 million ...